Canaccord initiated coverage of Heartflow (HTFL) with a Buy rating and $35 price target The firm believes the company’s artificial intelligence-based products are positioned to change the standard of care in the detection of coronary artery disease. Heartflow has “compelling” clinical and economic data, which is beginning to be reflected in society guidelines and reimbursement in the U.S., the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow initiated with a Buy at Stifel
- Heartflow initiated with an Overweight at JPMorgan
- Heartflow initiated with an Overweight at Piper Sandler
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential